Knight Long Term Investments vs Non Current Assets Total Analysis
GUD Stock | CAD 6.00 0.21 3.63% |
Knight Therapeutics financial indicator trend analysis is infinitely more than just investigating Knight Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Knight Therapeutics is a good investment. Please check the relationship between Knight Therapeutics Long Term Investments and its Non Current Assets Total accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
Long Term Investments vs Non Current Assets Total
Long Term Investments vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Knight Therapeutics Long Term Investments account and Non Current Assets Total. At this time, the significance of the direction appears to have strong relationship.
The correlation between Knight Therapeutics' Long Term Investments and Non Current Assets Total is 0.68. Overlapping area represents the amount of variation of Long Term Investments that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Knight Therapeutics, assuming nothing else is changed. The correlation between historical values of Knight Therapeutics' Long Term Investments and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Investments of Knight Therapeutics are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Long Term Investments i.e., Knight Therapeutics' Long Term Investments and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | 0.68 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Long Term Investments
Long Term Investments is an item on the asset side of Knight Therapeutics balance sheet that represents investments Knight Therapeutics intends to hold for over a year. Knight Therapeutics long term investments may include different instruments such as stocks, bonds, real estate and cash.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from Knight Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Knight Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. At this time, Knight Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 1st of June 2024, Enterprise Value Over EBITDA is likely to grow to 10.50, though Tax Provision is likely to grow to (4.9 M).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 3.6M | 6.6M | 12.5M | 9.4M | Depreciation And Amortization | 47.9M | 62.6M | 72.0M | 75.6M |
Knight Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Knight Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Knight Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.3B | 1.0B | 991.9M | 1.1B | 945.5M | 952.1M | |
Total Stockholder Equity | 810.7M | 886.2M | 842.0M | 825.9M | 746.9M | 823.4M | |
Net Debt | (107.1M) | (173.4M) | (45.0M) | 6.0M | 3.1M | 3.3M | |
Cash | 169.3M | 229.6M | 86.0M | 71.7M | 58.8M | 55.8M | |
Cash And Short Term Investments | 430.6M | 411.3M | 163.0M | 191.2M | 172.1M | 163.5M | |
Common Stock Total Equity | 761.5M | 761.8M | 723.8M | 694.4M | 798.5M | 616.3M | |
Common Stock Shares Outstanding | 140.1M | 132.0M | 124.5M | 114.9M | 101.2M | 123.2M | |
Total Current Assets | 698.2M | 554.6M | 307.3M | 395.6M | 365.1M | 556.5M | |
Common Stock | 723.8M | 694.4M | 628.9M | 599.1M | 688.9M | 628.1M | |
Other Current Liab | 225.6M | 15.9M | 11.7M | 15.0M | 1.0M | 993.7K | |
Total Current Liabilities | 350.8M | 114.1M | 105.3M | 141.3M | 114.0M | 96.9M | |
Net Tangible Assets | 1.0B | 549.1M | 652.0M | 416.3M | 374.7M | 569.1M | |
Property Plant And Equipment Net | 29.0M | 26.2M | 29.9M | 22.6M | 17.9M | 14.0M | |
Current Deferred Revenue | 282K | 183K | 39.9M | 14.6M | 16.8M | 8.9M | |
Retained Earnings | 52.2M | 174.5M | 191.6M | 161.8M | 150.9M | 178.6M | |
Accounts Payable | 72.8M | 44.5M | 65.3M | 106.1M | 85.4M | 89.6M | |
Non Current Assets Total | 607.1M | 485.0M | 684.6M | 659.2M | 580.4M | 435.2M | |
Other Assets | 152.0M | 75.5M | 57.1M | 15.6M | 17.9M | 17.0M | |
Net Receivables | 111.7M | 82.0M | 67.4M | 110.2M | 88.7M | 52.7M | |
Short Term Investments | 261.3M | 181.7M | 77.0M | 119.5M | 111.4M | 174.0M | |
Liabilities And Stockholders Equity | 1.3B | 1.0B | 991.9M | 1.1B | 1.2B | 1.0B | |
Inventory | 70.9M | 56.5M | 72.4M | 92.5M | 91.8M | 96.4M | |
Other Current Assets | 85.0M | 4.8M | 4.5M | 1.7M | 2.0M | 1.9M | |
Other Stockholder Equity | 17.2M | 18.8M | 21.9M | 23.8M | 27.3M | 15.8M | |
Total Liab | 390.2M | 153.4M | 149.9M | 229.0M | 198.6M | 130.2M | |
Long Term Investments | 259.7M | 174.8M | 179.0M | 158.0M | 120.0M | 183.4M | |
Property Plant And Equipment Gross | 29.0M | 26.2M | 41.0M | 56.1M | 39.5M | 21.3M | |
Accumulated Other Comprehensive Income | 17.4M | (1.5M) | (376K) | 41.3M | 37.1M | 39.0M | |
Short Term Debt | 52.3M | 53.6M | 28.3M | 20.3M | 18.2M | 17.3M | |
Intangible Assets | 173.4M | 156.5M | 350.3M | 338.8M | 290.0M | 149.3M | |
Property Plant Equipment | 29.0M | 26.2M | 29.9M | 22.6M | 26.0M | 13.4M | |
Other Liab | 4.6M | 29.6M | 36.8M | 31.9M | 36.7M | 38.5M | |
Non Current Liabilities Total | 39.4M | 39.4M | 44.6M | 87.7M | 84.6M | 88.8M | |
Non Currrent Assets Other | 52.7M | 47.3M | 47.9M | 48.2M | 43.4M | 70.6M | |
Long Term Debt Total | 9.8M | 2.5M | 12.7M | 57.4M | 66.1M | 69.4M | |
Capital Surpluse | 16.5M | 18.7M | 21.8M | 23.7M | 27.2M | 18.3M | |
Cash And Equivalents | 5.3M | 2.6M | 9.0M | 302K | 271.8K | 258.2K | |
Net Invested Capital | 866.3M | 938.0M | 877.9M | 895.9M | 808.7M | 732.4M | |
Net Working Capital | 270.7M | 438.0M | 199.7M | 254.3M | 251.1M | 331.3M | |
Capital Stock | 723.8M | 694.4M | 628.9M | 599.1M | 540.0M | 526.4M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. Note that the Knight Therapeutics information on this page should be used as a complementary analysis to other Knight Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Knight Stock analysis
When running Knight Therapeutics' price analysis, check to measure Knight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Knight Therapeutics is operating at the current time. Most of Knight Therapeutics' value examination focuses on studying past and present price action to predict the probability of Knight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Knight Therapeutics' price. Additionally, you may evaluate how the addition of Knight Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |